Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics after Helicobacter pylori eradication (Probiotics trial)
jRCTs031220708Active, not recruiting
- Sponsor
- Meiji Holdings Co., Ltd.
- Start
- May 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Lactobacillus gasseri OLL2716 in atrophic gastritis (AG), gastritis and gastric cancer (GC), sponsored by Meiji Holdings Co., Ltd. Primary endpoint: Gastric mucosal inflammation improvement. Started May 2023; status: active, not recruiting.
02
Drugs
Lactobacillus gasseri OLL2716
03
Conditions
atrophic gastritis (AG)gastritisgastric cancer (GC)
Beyond the preview
Go deeper on jRCTs031220708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220708.